Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 10/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 10/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.57 |
| ▸ | CTSL | P07711 | 1/20 | 0.56 |
| ▸ | CTSB | P07858 | 1/20 | 0.56 |
| ▸ | YTHDC1 | Q96MU7 | 2/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3451476 | 0.88 | ADORA3 (0.47) | ADORA3ADORA1ADORA2ACTSLCTSB | |
| SCHEMBL182902 | 0.82 | ADORA1 (0.63) | ADORA3ADORA1ADORA2AYTHDC1ADORA2B | |
| SCHEMBL7442349 | 0.81 | ADORA1 (0.64) | ADORA3ADORA1ADORA2AYTHDC1ADORA2B | |
| SCHEMBL17929772 | 0.80 | YTHDC1 (0.63) | ADORA3ADORA1ADORA2ACTSLCTSB | |
| SCHEMBL20180099 | 0.80 | CTSL (0.51) | ADORA3ADORA1ADORA2ACTSLCTSB | |
| SCHEMBL3451170 | 0.79 | CTSL (0.68) | ADORA3ADORA1ADORA2ACTSLCTSB | |
| SCHEMBL17262783 | 0.78 | YTHDC1 (0.61) | ADORA3ADORA1ADORA2ACTSLCTSB | |
| SCHEMBL16549253 | 0.77 | YTHDC1 (0.59) | ADORA3ADORA1ADORA2AYTHDC1ADORA2B | |
| SCHEMBL13057358 | 0.75 | CDK2 (0.61) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL21348744 | 0.75 | YTHDC1 (0.66) | ADORA3ADORA1ADORA2AYTHDC1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1537111-B1 | HETEREOARYL NITRILE DERIVATIVES | NOVARTIS AG (CH) | 2007-05-02 | — | — | EP | disclosed |
| US-20060142575-A1 | Hetereoaryl nitrile derivatives | NOVARTIS AG (CH) | 2006-06-29 | — | — | US | disclosed |
| EP-1537111-A1 | HETEREOARYL NITRILE DERIVATIVES | Novartis AG (CH) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004020441-A1 | HETEREOARYL NITRILE DERIVATIVES | NOVARTIS AG (CH) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142575-A1 | Hetereoaryl nitrile derivatives | CTSK, CTSZ, CTSE | ADORA3 3481/4885ADORA1 3391/4885ADORA2A 3905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.